Prothena
PRTA | NASDAQ
$7.97
-$0.19 (-2.33%)
At close: Nov 16, 2026, 4:00 PM ET
$7.97
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-2.33%
(1D)No price chart data available for 1D timeframe.
Rating
39.5
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #543/1021 (Top 53%)
Key Statistics
Market Data
Market Cap $409.26M
1D Range
7.86 8.18
52W Range
7.86 11.51
Valuation (TTM)
PE -16.60
PB 1.52
EV/EBITDA -5.62
Valuation (NTM)
Forward PE 320.16
Forward PEG 0.17
Price Target $30.00
Cash Flow
FCF Yield -7.9%
SBC Adj. FCF Yield -14.8%
SBC Impact -87.9%
Margins
Gross Margin 96.5%
Operating Margin -78.4%
FCF Margin -61.0%
Growth (CAGR)
Revenue 3Y | 5Y -27.9% |
-23.4%
Dil EPS 3Y | 5Y 36.7% |
7.4%
FCF 3Y | 5Y 49.1% |
7.7%
Returns
ROA -8.4%
ROE -8.3%
ROIC -15.0%
Financial Health
Net Cash
$265.11M
Current Ratio 23.95
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline i...
Sector Healthcare
Industry Biotechnology
Employees 67
IPO Date Dec 20, 2012
Website www.prothena.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.32
Miss -40.88%
YoY:
+52.24% REV
$620K
Miss -93.53%
YoY:
-74.33%Next Earnings
Feb 18, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$30.00
Upside
+276.41%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PRTA